Savara (SVRA) Non-Current Deferred Tax Liability (2011 - 2018)
Savara's (SVRA) quarterly Non-Current Deferred Tax Liability came in at $2.5 million in Q3 2018, down 77.5% year-on-year from $11.3 million in Q3 2017, and down 0.78% on a QoQ basis from $2.6 million in Q2 2018.
Savara (SVRA) Non-Current Deferred Tax Liability (2011 - 2018) Analysis & Trends
Savara (SVRA) has 8 years of Non-Current Deferred Tax Liability data on file, last reported at $2.5 million in Q3 2018.
- On a quarterly basis, Non-Current Deferred Tax Liability fell 77.5% year-over-year to $2.5 million in Q3 2018; TTM through Sep 2018 was $2.5 million, a 77.5% decrease from a year earlier, with the FY2017 full-year figure at $7.2 million, up 211.54% from the prior year.
- Non-Current Deferred Tax Liability for Q3 2018 stood at $2.5 million, down from $2.6 million in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for SVRA reached as high as $11.3 million in Q3 2017 and fell as low as $995000.0 in Q1 2017.
- Historically, Non-Current Deferred Tax Liability has averaged $4.1 million across 5 years, with a median of $3.4 million in 2014.
- Across the five-year window, Non-Current Deferred Tax Liability surged 230.88% in 2017 and plunged 77.5% in 2018, its largest moves.
- Year by year, Non-Current Deferred Tax Liability stood at $3.4 million in 2014, then changed by 0.0% to $3.4 million in 2015, then plunged by 32.29% to $2.3 million in 2016, then surged by 211.54% to $7.2 million in 2017, then slumped by 64.71% to $2.5 million in 2018.
- Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $2.5 million in Q3 2018, $2.6 million in Q2 2018, and $2.7 million in Q1 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Savara | 1.24 Bn | 1.24 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 2.53 Mn |
| Sep 30, 2018 | 2.53 Mn |
| Jun 30, 2018 | 2.55 Mn |
| Jun 30, 2018 | 2.55 Mn |
| Mar 31, 2018 | 2.69 Mn |
| Mar 31, 2018 | 2.69 Mn |
| Dec 31, 2017 | 7.18 Mn |
| Dec 31, 2017 | 7.18 Mn |
| Sep 30, 2017 | 11.26 Mn |
| Sep 30, 2017 | 11.26 Mn |
| Jun 30, 2017 | 11.18 Mn |
| Jun 30, 2017 | 11.18 Mn |
| Mar 31, 2017 | 995,000.00 |
| Mar 31, 2017 | 995,000.00 |
| Dec 31, 2016 | 2.31 Mn |
| Dec 31, 2016 | 2.31 Mn |
| Sep 30, 2016 | 3.40 Mn |
| Sep 30, 2016 | 3.40 Mn |
| Jun 30, 2016 | 3.40 Mn |
| Jun 30, 2016 | 3.40 Mn |